Haleon Pakistan Limited (PSX:HALEON)

Pakistan flag Pakistan · Delayed Price · Currency is PKR
756.89
+1.71 (0.23%)
At close: Jun 3, 2026
Market Cap88.60B +3.5%
Revenue (ttm)42.67B +8.6%
Net Income6.55B +24.1%
EPS55.96 +24.1%
Shares Out 117.05M
PE Ratio13.53
Forward PE11.52
Dividend30.00 (3.97%)
Ex-Dividend DateApr 21, 2026
Volume20,018
Open755.00
Previous Close755.18
Day's Range754.99 - 762.99
52-Week Range655.00 - 1,010.00
Beta0.47
AnalystsBuy
Price Target1,121.67 (+48.2%)
Earnings DateAug 28, 2026

About Haleon Pakistan

Haleon Pakistan Limited engages in the manufacture, marketing, and sale of pharmaceutical and consumer healthcare products in Pakistan, the Philippines, and Qatar. The company offers oral health, pain relief, wellness and nutrition, and respiratory health products. It sells its products primarily under the Panadol, CaC-1000 Plus, Sensodyne, paradontax, T-Day, ENO, Hydrozole, Qalsium-D, and Voltral Emulgel brands. The company was formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited and changed its name to Haleon Pakistan Limite... [Read more]

Industry Pharmaceutical Preparations
Founded 2015
Employees 451
Stock Exchange Pakistan Stock Exchange
Ticker Symbol HALEON
Full Company Profile

Financial Performance

In 2025, Haleon Pakistan's revenue was 43.11 billion, an increase of 15.86% compared to the previous year's 37.21 billion. Earnings were 6.37 billion, an increase of 39.21%.

Financial Statements